Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas

NCT01805037 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
20
Enrollment
OTHER
Sponsor class

Stopped Lack of funding

Conditions

Interventions

Sponsor

Northwestern University

Collaborators